(Q36613700)

15 August 2017

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma (English)

1 reference

15 August 2017

1 reference

1 reference

R L Jones

1

1 reference

15 August 2017

S R Lakhani

2

1 reference

15 August 2017

A E Ring

3

1 reference

15 August 2017

S Ashley

4

1 reference

15 August 2017

G Walsh

5

1 reference

15 August 2017

I E Smith

6

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

94

1 reference

15 August 2017

3

1 reference

15 August 2017

358-362

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6602950

15 August 2017

0 references

cites work

Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361141

Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361141

Clinical and pathological response to primary chemotherapy in operable breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361141

Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361141

Reporting results of cancer treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361141

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361141

A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361141

Nonparametric Estimation from Incomplete Observations

20 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602950

Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience

21 January 2018

1 reference

12 December 2020

CARCINOMA OF THE BREAST: II. CRITERIA OF OPERABILITY

1 reference

12 December 2020

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

1 reference

12 December 2020

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

12 December 2020

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

12 December 2020

Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer

1 reference

12 December 2020

Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome

1 reference

12 December 2020

Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status

1 reference

12 December 2020

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

12 December 2020

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6602950

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

1 reference